drugset / Trial / NCT05321940
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to investigate whether the combination of STING-dependent Adjuvants (STAVs) and dendritic cell (DC) vaccine therapies will increase the body's ability to fight aggressive relapsed or refractory leukemias.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | 1.5e+07 cells | Intravenous |
| Subject | DC vaccine | Vaccine | 2e+07 cells | Intravenous |
| Subject | STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells | Cell therapy | 5 ml | Intravenous |